Melasma (Chlosma) - Pipeline Review, H1 2017
Melasma (Chlosma) - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides an overview of the Melasma (Chlosma) (Dermatology) pipeline landscape.
Melasma is a common skin problem. The condition causes dark, discolored patches on your skin. The dark patches in melasma could be triggered by several factors, including pregnancy, birth control pills, hormone replacement therapy (HRT and progesterone), family history of melasma, race, antiseizure medications, and other medications that make the skin more prone to pigmentation after exposure to ultraviolet (UV) light.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melasma (Chlosma) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 2 respectively.
Melasma (Chlosma) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides an overview of the Melasma (Chlosma) (Dermatology) pipeline landscape.
Melasma is a common skin problem. The condition causes dark, discolored patches on your skin. The dark patches in melasma could be triggered by several factors, including pregnancy, birth control pills, hormone replacement therapy (HRT and progesterone), family history of melasma, race, antiseizure medications, and other medications that make the skin more prone to pigmentation after exposure to ultraviolet (UV) light.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melasma (Chlosma) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 2 respectively.
Melasma (Chlosma) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Melasma (Chlosma) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Melasma (Chlosma) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melasma (Chlosma) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melasma (Chlosma) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melasma (Chlosma) (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melasma (Chlosma) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melasma (Chlosma) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Melasma (Chlosma) - Overview
Melasma (Chlosma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Melasma (Chlosma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melasma (Chlosma) - Companies Involved in Therapeutics Development
EpiPharm AG
Hyundai Pharmaceutical Co Ltd
RXi Pharmaceuticals Corp
Melasma (Chlosma) - Drug Profiles
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-M13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPH-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranexamic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRY-26071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRY-26077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melasma (Chlosma) - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Melasma (Chlosma) - Overview
Melasma (Chlosma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Melasma (Chlosma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melasma (Chlosma) - Companies Involved in Therapeutics Development
EpiPharm AG
Hyundai Pharmaceutical Co Ltd
RXi Pharmaceuticals Corp
Melasma (Chlosma) - Drug Profiles
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-M13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPH-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranexamic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRY-26071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRY-26077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melasma (Chlosma) - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Melasma (Chlosma), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Melasma (Chlosma) - Pipeline by EpiPharm AG, H1 2017
Melasma (Chlosma) - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Melasma (Chlosma) - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Melasma (Chlosma) - Dormant Projects, H1 2017
Number of Products under Development for Melasma (Chlosma), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Melasma (Chlosma) - Pipeline by EpiPharm AG, H1 2017
Melasma (Chlosma) - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Melasma (Chlosma) - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Melasma (Chlosma) - Dormant Projects, H1 2017
LIST OF FIGURES
Number of Products under Development for Melasma (Chlosma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
EpiPharm AG
Hyundai Pharmaceutical Co Ltd
RXi Pharmaceuticals Corp
Number of Products under Development for Melasma (Chlosma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
EpiPharm AG
Hyundai Pharmaceutical Co Ltd
RXi Pharmaceuticals Corp
